The latest from the Invoke team
Invoke Bio Wins $100,000 QB3 Mentoring Program Award
Invoke Bio was awarded $100,000 through the QB3 Mentoring Program's Proof-of-Concept Award, supporting research and development for early-stage biotech companies. Co-Founder & CEO TJ Sears noted the funding will help catalyze the company's mission to deliver personalized immunotherapies for patients fighting cancer.
TJ Sears Named Co-Chair of US FNIH National Cancer Vaccines Initiative Subcommittee
Invoke Bio's Co-Founder & CEO, TJ Sears, was appointed Co-Chair of the Data Infrastructure & AI Strategy subcommittee within the Foundation for the National Institutes of Health (FNIH)-coordinated National Cancer Vaccines Initiative. This collaboration is a public-private partnership convening leading researchers, clinicians, and industry experts to accelerate the development and deployment of cancer vaccines in the US. The subcommittee is focused on data systems and computational approaches for antigen selection and learning across the national program.
New ML Tool Identifies Four Genetic Subtypes of Type 1 Diabetes — Enabling Earlier, Personalized Treatment
UC San Diego researchers developed T1GRS, a machine learning tool that predicts genetic risk for Type 1 diabetes across broader populations by analyzing complex gene interactions, uncovering four distinct disease subtypes with unique onset patterns and complication profiles.
Invoke Bio's NEMo: Evolutionary Machine Learning for Neoantigen Immunogenicity Prediction
NEMo uses evolutionary machine learning trained on 25,000+ immune checkpoint blockade mutations, treating immune-driven neoantigen elimination as a training signal. Validated across the TESLA benchmark and two cancer vaccine clinical trials.
NeoPrecis Beats Tumor Mutation Burden as a Predictor of Immunotherapy Response
By combining MHC-I/II neoantigen immunogenicity with tumor clonal architecture, NeoPrecis outperforms TMB across five melanoma and three NSCLC cohorts.
Foundation Model Trained on 30,000 Tumor Genomes Predicts Drug Resistance Across Cancer Types
MutationProjector projects tumor mutation profiles into unified biological coordinates, achieving best-in-class accuracy predicting immunotherapy and chemotherapy resistance — and uncovering unexpected biomarkers like KMT2A mutation.
ML and Genome-Wide Genetics Combine to Sharpen Type 1 Diabetes Risk Prediction
Integrating expanded genetic association data with machine learning improves polygenic risk stratification for type 1 diabetes well beyond current clinical approaches.
NeoPrecis: Enhancing Immunotherapy Response Prediction Through Integration of Qualified Immunogenicity and Clonality-Aware Neoantigen Landscapes
NeoPrecis is a computational framework that improves cancer immunotherapy response prediction by integrating neoantigen quality across MHC-I and MHC-II pathways with tumor clonal architecture. Validated in melanoma and non-small cell lung cancer, it outperforms traditional tumor mutation burden metrics in predicting patient response.
Germline and Somatic Integration Uncovers Two Distinct Immune Pathways to Checkpoint Blockade Response
ML analysis of integrated germline and somatic features reveals divergent immune mechanisms — including T-follicular helper infiltration in MHC class-I deficient tumors — explaining why some patients respond to ICB through unexpected routes.